Literature DB >> 30061253

Preoperative Evaluation of Myometrial Invasion in Endometrial Carcinoma: Prospective Intra-individual Comparison of Magnetic Resonance Volumetry, Diffusion-weighted and Dynamic Contrast-enhanced Magnetic Resonance Imaging.

Stefan Felix Thieme1, Federico Collettini1, Jalid Sehouli2, Lucio Biocca1, Alessandra Lella1, Moritz Wagner1, Jumana Almuheimid2, Helmut Plett2,3, Mustafa Zelal Muallem4.   

Abstract

AIM: The purpose of this prospective study was to compare the diagnostic performance of diffusion-weighted (DWI) and dynamic contrast-enhanced imaging (DCE) and volumetric analyses in the preoperative assessment of myometrial invasion in patients with endometrial carcinoma.
MATERIALS AND METHODS: Thirty-five patients with endometrial cancer underwent preoperative magnetic resonance imaging including DWI and DCE for evaluation of the depth of myometrial invasion and volumetric analyses [tumor volume (TV), uterine volume (UV), tumor to volume ratio (TVR=(TV/TU)×100)]. The results of the evaluations were compared to the histopathological examinations.
RESULTS: DWI and DCE showed a sensitivity and specificity in evaluating the depth of myometrial invasion of 92% and 96% and 92% and 86%, respectively, while volumetric analyses showed a sensitivity and specificity of 85% and 86% (TVR cut-off=10%) and 69% and 100% (TVR cut-off=25%), respectively.
CONCLUSION: DWI and DCE are both good diagnostic tools for the preoperative assessment of myometrial invasion. From our results and literature research, there is potential for omitting gadolinium-based contrast agents given the high diagnostic value of DWI. In our patient collective, the predictive power of volumetric analyses was lower than that of DWI. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  MR volumetry; Myometrial invasion; contrast-enhanced MRI; diffusion-weighted MRI; endometrial carcinoma; magnetic resonance imaging; preoperative staging

Mesh:

Substances:

Year:  2018        PMID: 30061253     DOI: 10.21873/anticanres.12791

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Quantitative assessment of diffusion kurtosis imaging depicting deep myometrial invasion: a comparative analysis with diffusion-weighted imaging.

Authors:  Jia-Cheng Song; Shan-Shan Lu; Jing Zhang; Xi-Sheng Liu; Cheng-Yan Luo; Ting Chen
Journal:  Diagn Interv Radiol       Date:  2020-03       Impact factor: 2.630

2.  ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.

Authors:  Nicole Concin; Carien L Creutzberg; Ignace Vergote; David Cibula; Mansoor Raza Mirza; Simone Marnitz; Jonathan A Ledermann; Tjalling Bosse; Cyrus Chargari; Anna Fagotti; Christina Fotopoulou; Antonio González-Martín; Sigurd F Lax; Domenica Lorusso; Christian Marth; Philippe Morice; Remi A Nout; Dearbhaile E O'Donnell; Denis Querleu; Maria Rosaria Raspollini; Jalid Sehouli; Alina E Sturdza; Alexandra Taylor; Anneke M Westermann; Pauline Wimberger; Nicoletta Colombo; François Planchamp; Xavier Matias-Guiu
Journal:  Virchows Arch       Date:  2021-02       Impact factor: 4.064

3.  Injection rate of contrast medium affects diagnostic ability of dynamic contrast-enhanced magnetic resonance imaging for endometrial carcinoma: a prospective cohort study.

Authors:  Donghui Xu; Aiping Jin; Yongqian Ge; Yanmei Zhang
Journal:  Gland Surg       Date:  2021-08

4.  Magnetic resonance imaging pitfalls in determining myometrial invasion in stage I endometrial cancer: A case report and literature review.

Authors:  Hariyono Winarto; Muhammad Habiburrahman; Trifonia Pingkan Siregar; Kartiwa Hadi Nuryanto
Journal:  Radiol Case Rep       Date:  2022-05-29

5.  Endometrial carcinoma: use of tracer kinetic modeling of dynamic contrast-enhanced MRI for preoperative risk assessment.

Authors:  Zhijun Ye; Gang Ning; Xuesheng Li; Tong San Koh; Huizhu Chen; Wanjing Bai; Haibo Qu
Journal:  Cancer Imaging       Date:  2022-03-09       Impact factor: 3.909

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.